{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:28:22Z","timestamp":1789597702930,"version":"build-2803163510"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.3497","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T15:01:11Z","timestamp":1617030071000},"page":"e213497","source":"Crossref","is-referenced-by-count":16,"title":["Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma"],"prefix":"10.1001","volume":"4","author":[{"given":"Hedwig M.","family":"Blommestein","sequence":"first","affiliation":[{"name":"Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margreet G.","family":"Franken","sequence":"additional","affiliation":[{"name":"Institute of Medical Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrissy H. Y.","family":"van Beurden-Tan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M. A.","family":"Blijlevens","sequence":"additional","affiliation":[{"name":"Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Huijgens","sequence":"additional","affiliation":[{"name":"Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carin A.","family":"Uyl-de Groot","sequence":"additional","affiliation":[{"name":"Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, the Netherlands"},{"name":"Institute of Medical Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[{"name":"Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,3,29]]},"reference":[{"issue":"2","key":"zoi210127r3","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/ejh.2016.96.issue-2","article-title":"A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model.","volume":"96","author":"Blommestein","year":"2016","journal-title":"Eur J Haematol"},{"issue":"1","key":"zoi210127r4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/bjh.14193","article-title":"Multiple myeloma: practice patterns across Europe.","volume":"175","author":"Raab","year":"2016","journal-title":"Br J Haematol"},{"issue":"2","key":"zoi210127r5","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bjh.2016.175.issue-2","article-title":"Multiple myeloma: patient outcomes in real-world practice.","volume":"175","author":"Yong","year":"2016","journal-title":"Br J Haematol"},{"issue":"2","key":"zoi210127r6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"zoi210127r7","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma.","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"issue":"14","key":"zoi210127r8","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma.","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi210127r9","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma.","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi210127r10","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma.","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"issue":"10068","key":"zoi210127r11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"11","key":"zoi210127r12","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"zoi210127r13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10","key":"zoi210127r14","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"issue":"8","key":"zoi210127r15","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma.","volume":"36","author":"Siegel","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi210127r16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40273-016-0455-3","article-title":"Modeling treatment sequences in pharmacoeconomic models.","volume":"35","author":"Zheng","year":"2017","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"zoi210127r17","first-page":"204","article-title":"Estimating the costs of therapy in patients with relapsed and\/or refractory multiple myeloma: a model framework.","volume":"8","author":"Roy","year":"2015","journal-title":"Am Health Drug Benefits"},{"issue":"5","key":"zoi210127r18","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3109\/0284186X.2015.1096021","article-title":"Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.","volume":"55","author":"Borg","year":"2016","journal-title":"Acta Oncol"},{"issue":"1","key":"zoi210127r19","first-page":"29","article-title":"Cost-effectiveness of drugs to treat relapsed\/refractory multiple myeloma in the united states.","volume":"24","author":"Carlson","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"issue":"11","key":"zoi210127r20","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1080\/13696998.2016.1194278","article-title":"Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.","volume":"19","author":"Jakubowiak","year":"2016","journal-title":"J Med Econ"},{"issue":"12","key":"zoi210127r21","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1080\/17474086.2017.1391088","article-title":"Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States.","volume":"10","author":"Jakubowiak","year":"2017","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"zoi210127r22","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s40273-015-0260-4","article-title":"A practical guide for using registry data to inform decisions about the cost effectiveness of new cancer drugs: lessons learned from the PHAROS registry.","volume":"33","author":"Blommestein","year":"2015","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"zoi210127r23","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000045","article-title":"Long-term outcomes in patients with multiple myeloma: a retrospective analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS).","volume":"2","author":"Verelst","year":"2018","journal-title":"Hemasphere"},{"issue":"8","key":"zoi210127r24","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/j.1524-4733.2010.00775.x","article-title":"Discrete event simulation: the preferred technique for health economic evaluations?","volume":"13","author":"Caro","year":"2010","journal-title":"Value Health"},{"issue":"14","key":"zoi210127r25","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.ejca.2011.04.034","article-title":"The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts.","volume":"47","author":"van de Poll-Franse","year":"2011","journal-title":"Eur J Cancer"},{"issue":"12","key":"zoi210127r26","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1200\/JCO.2016.71.1663","article-title":"Systematic literature review and network meta-analysis of treatment outcomes in relapsed and\/or refractory multiple myeloma.","volume":"35","author":"van Beurden-Tan","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi210127r27","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3324\/haematol.2018.206912","article-title":"Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis.","volume":"104","author":"Blommestein","year":"2019","journal-title":"Haematologica"},{"issue":"22","key":"zoi210127r28","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma.","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"10218","key":"zoi210127r29","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"zoi210127r30","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"zoi210127r32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/jcpt.12020","article-title":"Real-world health care costs of relapsed\/refractory multiple myeloma during the era of novel cancer agents.","volume":"38","author":"Gaultney","year":"2013","journal-title":"J Clin Pharm Ther"},{"issue":"10","key":"zoi210127r33","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1016\/j.clinthera.2017.08.010","article-title":"Cost-effectiveness of pomalidomide, carfilzomib, and daratumumab for the treatment of patients with heavily pretreated relapsed-refractory multiple myeloma in the United States.","volume":"39","author":"Pelligra","year":"2017","journal-title":"Clin Ther"},{"issue":"4","key":"zoi210127r36","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1.","volume":"14","author":"Jansen","year":"2011","journal-title":"Value Health"},{"issue":"4","key":"zoi210127r37","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1200\/JCO.2012.41.6180","article-title":"Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.","volume":"31","author":"San Miguel","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"zoi210127r38","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1200\/JCO.2013.52.0023","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.","volume":"32","author":"Paulmbo","year":"2014","journal-title":"J Clin Oncol"},{"key":"zoi210127r31","volume-title":"Richtlijn Voor Het Uitvoeren Van Economische Evaluaties in De Gezondheidszorg","author":"Zorginstituut Nederland","year":"2016"},{"key":"zoi210127r34","volume-title":"Kosteneffectiviteit in De Praktijk","author":"Zwaap","year":"2015"},{"key":"zoi210127r1","unstructured":"European Cancer Information System. Estimates of cancer incidence and mortality in 2020, for all cancer sites, estimated incidence by cancer\u2014summary: multiple myeloma. Accessed January 27, 2021. https:\/\/ecis.jrc.ec.europa.eu\/explorer.php"},{"key":"zoi210127r2","unstructured":"National Cancer Institute; Surveillance, Epidemiology, and End Results Program (SEER): Cancer stat facts: myeloma. Accessed January 26, 2021. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"zoi210127r35","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal, 2013. Published April 4, 2013. Accessed February 24, 2021. https:\/\/www.nice.org.uk\/process\/pmg9\/resources\/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2777838\/blommestein_2021_oi_210127_1616014076.29865.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T15:01:19Z","timestamp":1617030079000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2777838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,29]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.3497","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,29]]}}}